(38 days)
No
The document describes a mechanical biopsy device and its use with existing imaging systems, with no mention of AI or ML for image analysis, diagnosis, or device control.
No
The device is described as a "diagnostic device" used to "obtain localized large core biopsies" and "provide tissue for histological examination." Its purpose is to aid in diagnosis, not to treat a disease or condition.
Yes
The "Intended Use / Indications for Use" section explicitly states, "SiteSelect is a disposable, single use, diagnostic device used to obtain localized large core biopsies of breast tissue..." and "The SiteSelect device is intended to provide tissue for histological examination...". Obtaining tissue for histological examination to determine malignancy is a diagnostic purpose.
No
The device is described as a "disposable, single use, diagnostic device" used to obtain "large core biopsies of breast tissue." It is also compared to other physical biopsy devices and mentions "construction, materials, sterilization, and method of operation." This clearly indicates a physical medical device, not a software-only one.
Based on the provided text, the SiteSelect device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVDs are used to examine specimens from the human body. The SiteSelect device is used within the human body to obtain a tissue sample.
- The intended use is to obtain tissue for histological examination. The device itself is not performing the diagnostic test on the tissue. The diagnostic test (histological examination) is performed after the tissue is obtained using the SiteSelect device.
- The device is a biopsy device. Biopsy devices are generally considered surgical instruments used to collect samples, not IVDs that analyze those samples.
The text clearly describes the SiteSelect device as a tool for obtaining a tissue sample from the breast for subsequent histological examination. This places it in the category of a surgical or biopsy device, not an IVD.
N/A
Intended Use / Indications for Use
SiteSelect is a disposable, single use, diagnostic device used to obtain localized large core biopsies of breast tissue of a mammographic abnormality, identified by the placement of a needle/ localization wire, which is suspect to be malignant. The SiteSelect device is intended to provide tissue for histological examination with partial or complete removal of imaged lesions. The scope of a histological abnormality is not able to be determined from it's mammographic appearance. Therefore, it is essential that the tissue margins be examined for margin involvement and completeness of removal in cases where the tissue sample is not found to be benign.
SiteSelect is to be used in conjunction with stereotactic mammographic imaging systems capable of determining position of lesion within breast tissue.
This device is used in conjunction with the SiteSelect Instrument Accessories, which are mounted on a stereotactic table and used with a stereotactic mammographic imaging system.
Product codes
KNW
Device Description
The SiteSelect device, a disposable breast biopsy device, is substantially equivalent to like devices in commercial distribution. These devices are marketed by Imagyn Surgical and United States Surgical Corporation (USSC).
SiteSelect, Imagyn Surgical, and USSC devices are all used to obtain biopsies within breast tissue. These devices are used in conjunction with instrument accessories which are used to mount the devices on a stereotactic table. These devices are used with stereotactic mammographic imaging systems.
The construction, materials, sterilization, and method of operation of the SiteSelect devices are identical to the Imagyn Surgical SiteSelect devices currently on the market.
The major difference between SiteSelect and USSC ABBI devices is that the ABBI device removes tissue in route to and including the target area. The SiteSelect device obturates up to the lesion, leaving intact the tissue in route to the target area.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
stereotactic mammographic imaging systems
Anatomical Site
breast tissue
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Data from a multi-center, non-randomized study was collected. Eighty-seven patients, from 3 sites, underwent SiteSelect stereotactic breast biopsy procedures to evaluate device for the use in the removal of mammographically detected abnormalities for diagnostic evaluation.
Twelve patients (14%) were diagnosed with malignant lesions. Of the 12 patients with malignant lesions 2 (16.7%) had negative margins, 7 (58.3%) had margin involvement, and 3 (25%) were undetermined. Consistent with standard of care for excisional biopsies, all patients with malignancies were treated with a surgical procedure after diagnostic SiteSelect procedure.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.1075 Gastroenterology-urology biopsy instrument.
(a)
Identification. A gastroenterology-urology biopsy instrument is a device used to remove, by cutting or aspiration, a specimen of tissue for microscopic examination. This generic type of device includes the biopsy punch, gastrointestinal mechanical biopsy instrument, suction biopsy instrument, gastro-urology biopsy needle and needle set, and nonelectric biopsy forceps. This section does not apply to biopsy instruments that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.(b)
Classification. (1) Class II (performance standards).(2) Class I for the biopsy forceps cover and the non-electric biopsy forceps. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
0
DEC 27 1999
K99 39 36
Appendix II
Summary of Safety and Effectiveness
The SiteSelect device, a disposable breast biopsy device, is substantially equivalent to like devices in commercial distribution. These devices are marketed by Imagyn Surgical and United States Surgical Corporation (USSC).
SiteSelect, Imagyn Surgical, and USSC devices are all used to obtain biopsies within breast tissue. These devices are used in conjunction with instrument accessories which are used to mount the devices on a stereotactic table. These devices are used with stereotactic mammographic imaging systems.
The construction, materials, sterilization, and method of operation of the SiteSelect devices are identical to the Imagyn Surgical SiteSelect devices currently on the market.
The major difference between SiteSelect and USSC ABBI devices is that the ABBI device removes tissue in route to and including the target area. The SiteSelect device obturates up to the lesion, leaving intact the tissue in route to the target area.
Standards/guidelines used for the testing and manufacturing of the SiteSelect device are:
ANSI/AAMI/ISO 11135-1994 Medical Devices - Validation and routine control of ethylene oxide sterilization ANSI/AAMI/ISO 11135-1994 Medical Devices -Validation and routine control of ethylene oxide sterilization
ISO 10993-7: 1995 EtO Sterilization Residuals; for Limited Exposure Devices
FDA's Proposed Residue Limits; FDA, 43FR 279.82 (June 23, 1978)
ISO-10993 Biological evaluation of Medical Devices Part 1: Evaluation and Testing
EN 1441 Risk Analysis
ISO 11607 Packaging for Sterilized Devices
1
Appendix II
Summary of Safety and Effectiveness (continued)
Clinical Summary:
Data from a multi-center, non-randomized study was collected. Eighty-seven patients, from 3 sites, underwent SiteSelect stereotactic breast biopsy procedures to evaluate device for the use in the removal of mammographically detected abnormalities for diagnostic evaluation.
Twelve patients (14%) were diagnosed with malignant lesions. Of the 12 patients with malignant lesions 2 (16.7%) had negative margins, 7 (58.3%) had margin involvement, and 3 (25%) were undetermined. Consistent with standard of care for excisional biopsies, all patients with malignancies were treated with a surgical procedure after diagnostic SiteSelect procedure.
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol resembling a stylized bird or human profile, composed of three curved lines.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
DEC 2 7 1999
Ms. Julie Powell Quality Assurance/Regulatory Affairs Director Imagyn Surgical 8850 M89, Box 351 Richland, Michigan 49083-0351
K993936 Re: Trade Name: SiteSelect Breast Biopsy Device Regulatory Class: II Product Code: KNW Dated: November 18, 1999 Received: November 19, 1999
Dear Ms. Powell:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
Page 2 - Ms. Julie Powell
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Rindtliya
Sor Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Page 1 of 1
510(k) Number (if known):
Device Name:
Indications for Use:
SiteSelect is a disposable, single use, diagnostic device used to obtain localized large core biopsies of breast tissue of a mammographic abnormality, identified by the placement of a needle/ localization wire, which is suspect to be malignant. The SiteSelect device is intended to provide tissue for histological examination with partial or complete removal of imaged lesions. The scope of a histological abnormality is not able to be determined from it's mammographic appearance. Therefore, it is essential that the tissue margins be examined for margin involvement and completeness of removal in cases where the tissue sample is not found to be benign.
SiteSelect is to be used in conjunction with stereotactic mammographic imaging systems capable of determining position of lesion within breast tissue.
This device is used in conjunction with the SiteSelect Instrument Accessories, which are mounted on a stereotactic table and used with a stereotactic mammographic imaging system.
(PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED.)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| (Division Sign-Off) | |
|---|---|
| Division of General Restorative Devices | |
| 510(k) Number | K957556 |
| Prescription Use | X | OR | Over-the-Counter Use | |
|---|---|---|---|---|
| (Per 21 CFR 801.1091 | (Optional Format 1-2-96) |